- Home
- BME vs KRRO Comparison
BME vs KRRO Comparison
Compare BME & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BME
- KRRO
- Stock Information
- Founded
- BME 2005
- KRRO 2014
- Country
- BME United States
- KRRO United States
- Employees
- BME N/A
- KRRO N/A
- Industry
- BME Trusts Except Educational Religious and Charitable
- KRRO Biotechnology: Pharmaceutical Preparations
- Sector
- BME Finance
- KRRO Health Care
- Exchange
- BME Nasdaq
- KRRO Nasdaq
- Market Cap
- BME 525.3M
- KRRO 490.1M
- IPO Year
- BME N/A
- KRRO 2019
- Fundamental
- Price
- BME $38.13
- KRRO $48.04
- Analyst Decision
- BME
- KRRO Strong Buy
- Analyst Count
- BME 0
- KRRO 7
- Target Price
- BME N/A
- KRRO $133.83
- AVG Volume (30 Days)
- BME 34.0K
- KRRO 121.8K
- Earning Date
- BME 01-01-0001
- KRRO 11-12-2024
- Dividend Yield
- BME 6.26%
- KRRO N/A
- EPS Growth
- BME N/A
- KRRO N/A
- EPS
- BME 1.44
- KRRO N/A
- Revenue
- BME N/A
- KRRO N/A
- Revenue This Year
- BME N/A
- KRRO N/A
- Revenue Next Year
- BME N/A
- KRRO N/A
- P/E Ratio
- BME $28.37
- KRRO N/A
- Revenue Growth
- BME N/A
- KRRO N/A
- 52 Week Low
- BME $35.53
- KRRO $30.01
- 52 Week High
- BME $43.20
- KRRO $98.00
- Technical
- Relative Strength Index (RSI)
- BME 29.90
- KRRO 49.74
- Support Level
- BME $38.00
- KRRO $41.14
- Resistance Level
- BME $39.24
- KRRO $51.95
- Average True Range (ATR)
- BME 0.36
- KRRO 5.75
- MACD
- BME -0.09
- KRRO 0.44
- Stochastic Oscillator
- BME 6.97
- KRRO 66.74
About BME Blackrock Health Sciences Trust
Blackrock Health Sciences Trust has an investment objective to provide total return through a combination of current income, current gains, and long-term capital appreciation. The Fund invests 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives.
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.